Teva Pharmaceutical Industries (TEVA)
(Delayed Data from NYSE)
$17.73 USD
+0.01 (0.06%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $17.73 0.00 (0.00%) 5:28 PM ET
3-Hold of 5 3
A Value B Growth A Momentum A VGM
Income Statements
Fiscal Year end for Teva Pharmaceutical Industries Ltd falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 15,846 | 14,925 | 15,878 | 16,659 | 16,887 |
Cost Of Goods | 8,200 | 7,952 | 8,284 | 8,933 | 9,351 |
Gross Profit | 7,646 | 6,973 | 7,594 | 7,726 | 7,536 |
Selling & Adminstrative & Depr. & Amort Expenses | 7,213 | 9,072 | 5,879 | 6,669 | 7,980 |
Income After Depreciation & Amortization | 433 | -2,099 | 1,715 | 1,057 | -444 |
Non-Operating Income | -1,057 | -966 | -1,058 | -5,462 | -822 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -624 | -3,065 | 658 | -4,406 | -1,265 |
Income Taxes | -7 | -638 | 211 | -168 | -278 |
Minority Interest | -56 | -53 | 39 | -109 | -2 |
Investment Gains/Losses | 2 | 21 | 9 | 138 | -13 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -615 | -2,406 | 456 | -4,100 | -1,000 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -559 | -2,353 | 417 | -3,990 | -998 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 1,586 | -791 | 3,045 | 2,614 | 1,278 |
Depreciation & Amortization (Cash Flow) | 1,153 | 1,308 | 1,330 | 1,557 | 1,722 |
Income After Depreciation & Amortization | 433 | -2,099 | 1,715 | 1,057 | -444 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 1,119.00 | 1,110.00 | 1,107.00 | 1,095.00 | 1,091.00 |
Diluted EPS Before Non-Recurring Items | 2.46 | 2.42 | 2.48 | 2.45 | 2.31 |
Diluted Net EPS (GAAP) | -0.50 | -2.12 | 0.38 | -3.64 | -0.91 |
Fiscal Year end for Teva Pharmaceutical Industries Ltd falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 4,164.00 | 3,819.00 | 4,457.00 | 3,850.00 | 3,878.00 |
Cost Of Goods | 2,140.00 | 2,048.00 | 2,040.00 | 1,999.00 | 2,082.00 |
Gross Profit | 2,024.00 | 1,771.00 | 2,417.00 | 1,851.00 | 1,796.00 |
SG&A, R&D, and Dept/Amort Expenses | 2,030.00 | 1,988.00 | 1,695.00 | 1,495.00 | 2,442.00 |
Income After SG&A, R&D, and Dept/Amort Expenses | -6.00 | -217.00 | 722.00 | 356.00 | -646.00 |
Non-Operating Income | -241.00 | -250.00 | -249.00 | -280.00 | -268.00 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -246.00 | -467.00 | 473.00 | 75.00 | -914.00 |
Income Taxes | 630.00 | -52.00 | 40.00 | -12.00 | -16.00 |
Minority Interest | -29.00 | -280.00 | 4.00 | 8.00 | -35.00 |
Investment Gains/Losses | 2.00 | -4.00 | 3.00 | 0.00 | -1.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -874.00 | -419.00 | 436.00 | 87.00 | -899.00 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -845.00 | -139.00 | 429.00 | 80.00 | -863.00 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 1,133.00 | 1,123.00 | 1,137.00 | 1,135.00 | 1,120.00 |
Diluted EPS Before Non-Recurring Items | 0.58 | 0.46 | 0.98 | 0.58 | 0.54 |
Diluted Net EPS (GAAP) | -0.75 | -0.12 | 0.38 | 0.07 | -0.77 |